Skip to content

The ELUTES Clinical Trial

The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00225654
Acronym
ELUTES I
Enrollment
192
Registered
2005-09-26
Start date
2000-01-31
Completion date
2001-11-30
Last updated
2012-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery, stent, drug eluting, patency, restenosis

Brief summary

ELUTES is a European multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Paclitaxel Eluting V-Flex Plus coronary stent to reduce restenosis in the coronary artery.

Interventions

Sponsors

Cook Group Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. * Patient must be an acceptable candidate for coronary artery bypass surgery. * Patient or legal guardian must have signed informed consent. * Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram.

Exclusion criteria

* Patient must be less than 18 years old. * Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. * Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. * Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. * Women of child bearing potential. * Patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy. * Patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure.

Design outcomes

Primary

MeasureTime frame
Angiographic in-stent % diameter stenosis and late loss at follow up.

Secondary

MeasureTime frame
Major adverse events
Total lesion revascularization

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026